ロード中...

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

The management of Parkinson's disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complications of ther...

詳細記述

保存先:
書誌詳細
出版年:Pharmacol Res Perspect
主要な著者: Sjöberg, Folke, Waters, Susanna, Löfberg, Boel, Sonesson, Clas, Waters, Nicholas, Tedroff, Joakim
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8137807/
https://ncbi.nlm.nih.gov/pubmed/34018344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.792
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!